ReviewCells2019
Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- An Immunothrombotic Extracellular Vesicle mRNA Profile Associated with Thrombosis in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Neutrophil extracellular traps induce chemoresistance in human breast cancer cells through the PI3K/AKT/NF-κB pathway.Frontiers in immunology · 2026Article
- Optimizing Extracellular Vesicles for Cardiac Repair Post-Myocardial Infarction: Approaches and Challenges.Biomolecules · 2025Review
- Dual implication of endothelial adhesion molecules in tumor progression and cancer immunity.Cell adhesion & migration · 2025Review
- Cancer Cell-Derived Large Extracellular Vesicles Promote Venous Thromboembolism by Activating NETosis Through Delivering CYBA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Coagulation protease-induced extracellular vesicles: their potential effects on coagulation and inflammation.Journal of thrombosis and haemostasis : JTH · 2024Review
- The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2024Review
- Exomap1 mouse: A transgenic model forExtracellular vesicle · 2023Article
- Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?International journal of molecular sciences · 2023Review
- Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications.Extracellular vesicles and circulating nucleic acids · 2023Article
- Mechanism of Tumor-Platelet Communications in Cancer.Circulation research · 2023Article
- Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer.Journal of stroke · 2023Article
- Zoster-Associated Prothrombotic Plasma Exosomes and Increased Stroke Risk.The Journal of infectious diseases · 2023Article
- A crucial exosome-related gene pair (Frontiers in immunology · 2023Article
- Prognostic Value of Platelet Aggregation Function in Patients with laryngeal Carcinoma.International journal of general medicine · 2023Article
- Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.Journal of clinical medicine · 2022Review
- Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.Cancer metastasis reviews · 2022Review
- Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation.International journal of molecular sciences · 2022Review
- The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The establishment of prothrombotic states during cancer progression is well reported but the precise mechanisms underlying this process remain elusive. A number of studies have implicated the presence of the clotting initiator protein, tissue factor (TF), in circulating tumor-derived extracellular vesicles (EVs) with thrombotic manifestations in certain cancer types. Tumor cells, as well as tumor-derived EVs, may activate and promote platelet aggregation by TF-dependent and independent pathways. Cancer cells and their secreted EVs may also facilitate the formation of neutrophil extracellular traps (NETs), which may contribute to thrombus development. Alternatively, the presence of polyphosphate (polyP) in tumor-derived EVs may promote thrombosis through a TF-independent route. We conclude that the contribution of EVs to cancer coagulopathy is quite complex, in which one or more mechanisms may take place in a certain cancer type. In this context, strategies that could attenuate the crosstalk between the proposed pro-hemostatic routes could potentially reduce cancer-associated thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.